Welcome to BioSeeker Group!

Promising Drug Discovery Tools in Antifungal and Status on Emerging Novel Targets

Additional Information

Published Date Aug 24, 2004
Pages 91
PDF Fact Sheet View Fact Sheet for the report Promising Drug Discovery Tools in Antifungal and Status on Emerging Novel Targets in PDF
Format PDF
Publisher BioSeeker Group

Availability: In stock

$1,195.00

Quick Overview

This report will give you a comprehensive overview of the emerging novel drug targets as well as the new generation of antifungal drugs in clinical trials.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Promising Drug Discovery Tools in Antifungal and Status on Emerging Novel Targets.

    To find out more about Promising Drug Discovery Tools in Antifungal and Status on Emerging Novel Targets, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Promising Drug Discovery Tools in Antifungal and Status on Emerging Novel Targets is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

The antifungal market is steadily growing and fungal infections is today the third most common hospital-acquired infection. The global market is estimated to be worth more than $3 billion USD. Fungal infections have emerged as a growing threat to human health. Two important reasons for this are the number of HIV infected patients and the increasing number of patients treated with cancer chemotherapy drugs. This has formed an ever-expanding number of immuno-compromised individuals at risk for opportunistic infections. As a result several companies have searched for novel molecular targets for new antifungal drugs, by using modern genomic approaches. The goal of a safe prophylactic antifungal therapy may not be far away from being realized, and a success would definitely provide significant revenues.

This report will give you a comprehensive overview of the emerging novel drug targets as well as the new generation of antifungal drugs in clinical trials. Moreover, you will find an up to date outlook of the collaborative landscape of fungal drug discovery. BioSeeker has also investigated the ongoing development of promising screening and assay technologies of importance for further development of new antifungal drugs.

We place special emphasis on glycosylphosphatidylinositol (GPI) anchoring, ABC phospholipid translocators, elongation factor-2 and calcineurin. Extensive scientific research is being conducted in these areas and important breakthroughs are expected earlier than for other novel targets. Many novel targets for antifungal therapy are in early stages of research and development (research, preclinical and phase I studies), and will take at least five to ten years to reach the market. This 80+ page report focuses on recent achievements made in antifungal target discovery and screening assays used to identify novel lead antifungal compounds. BioSeeker Group has identified an array of companies involved in this development and their recent activities are described.

Topics considered in this report are:

  • Research: identified targets & new assays for drug screening
  • Clinical trials: Ongoing studies of potential antifungal drugs
  • Patents: selected near term key patents
  • Partnerships: key collaborations for success

Companies mentioned in this report:

Abbott Laboratories, Advanced Bio-Technologies , Anadys, ARIAD Pharmaceuticals, Inc, Arrow Therapeutics , AstraZeneca, Aventis , Basilea Pharmaceutica AG, Bayer-AG, Bioqual Inc., Bristol-Myers Squibb, Celera , Demegen, Discovery Technologies, Dyadic , Eisai Co Ltd, Eli Lilly, Elitra, Essential Therapeutics, Fujisawa Pharmaceutical Co, Genelabs, GlaxoSmithKline, GPC Biotech AG, Isis Innovation Ltd, Janssen Pharmaceutica, LG Chemical, Merck, MerLion Pharma, Microbia Inc., Millennium Pharm Inc, Mycologics, Neutec Pharma Plc, Novartis, Novo Nordisk AS, Pfizer, Pharmacia Corp., Pliva Pharmaceutical, Roche, Rosetta Inpharmatics Inc., Wyeth (American Home Prod), Sankyo Co., Ltd, Spirogen, Toyama Chemical Co., Ltd., Tularik Inc., VDDI Pharmaceuticals, Versicor Ltd, Xencor, Inc, Xenova Ltd, Xoma (US) LLC

EXECUTIVE SUMMARY
ABOUT BIOSEEKER GROUP
Our Five Steps to Creating Success in Intelligence
Databases
Reports
Analytical Tools
Consulting
Intelligence Partnership
METHODOLOGY
Information Sources
INTRODUCTION
Box 1. Common Fungal infections.
Box 2. Antifungal targets
WHEN WILL ANTIFUNGALS BE VIABLE AS PROPHYLAXES?
EMERGING ANTIFUNGAL TARGETS
Box3. Platform & Potential Lead compound strategies
Cell Wall Targets
Targeting Cell Adhesion
The Cytoplasmic Membrane
Drug Resistance
Inhibiting Drug Resistance by Targeting the Zn2Cys6 Cluster
Companies Targeting Cell-membrane Targets
DNA and protein synthesis
Elongation factors
Myristoylation
Prolyl isomerase
Key metabolical pathways
Glyoxalate cycle
Amino acid biosynthesis
Signal Transduction
Protein kinases
Protein phosphatases
Emerging Novel Targets
Cell cycle
Peptides influencing the membrane:
Novel antifungal agents in clinical trials
THE COLLABORATIVE LANDSCAPE IN ANTIFUNGAL DRUG DISCOVERY
Companies with more than 3 different business interactions
DRUG DISCOVERY PLATFORMS
Screening technologies focused cell wall targets
High-throughput screening systems aimed for fungal drug discovery
Platform companies that covers systems from screening assays to late stage development
Other interesting drug discovery assays
Academia, are they the future?
CONCLUSION
SELECTED COMPANY PROFILES
Anadys Pharmaceuticals Inc
Bayer AG
Bioqual Inc
Celera Genomics Group
Discovery Technologies
Dyadic International Inc
Elitra Pharmaceuticals
GPC Biotech AG
Isis Innovation Ltd
Mycologics
Novo Nordisk A/S
Toyama Chemical Co. Ltd
DISCLAIMER
Liability
Completeness
INDEX
APPENDIX I: COLLABORATIONS IN ANTIFUNGAL DRUG DISCOVERY.

Abbott Laboratories, Advanced Bio-Technologies , Anadys, ARIAD Pharmaceuticals, Inc, Arrow Therapeutics , AstraZeneca, Aventis , Basilea Pharmaceutica AG, Bayer-AG, Bioqual Inc., Bristol-Myers Squibb, Celera , Demegen, Discovery Technologies, Dyadic , Eisai Co Ltd, Eli Lilly, Elitra, Essential Therapeutics, Fujisawa Pharmaceutical Co, Genelabs, GlaxoSmithKline, GPC Biotech AG, Isis Innovation Ltd, Janssen Pharmaceutica, LG Chemical, Merck, MerLion Pharma, Microbia Inc., Millennium Pharm Inc, Mycologics, Neutec Pharma Plc, Novartis, Novo Nordisk AS, Pfizer, Pharmacia Corp., Pliva Pharmaceutical, Roche, Rosetta Inpharmatics Inc., Wyeth (American Home Prod), Sankyo Co., Ltd, Spirogen, Toyama Chemical Co., Ltd., Tularik Inc., VDDI Pharmaceuticals, Versicor Ltd, Xencor, Inc, Xenova Ltd, Xoma (US) LLC

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Promising Drug Discovery Tools in Antifungal and Status on Emerging Novel Targets.
    To find out more about Promising Drug Discovery Tools in Antifungal and Status on Emerging Novel Targets, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Promising Drug Discovery Tools in Antifungal and Status on Emerging Novel Targets is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Drug Discovery' category:


Promising Drug Discovery Tools in Antifungal and Status on Emerging Novel Targets
This report will give you a comprehensive overview of the emerging novel drug targets as well as the new generation of antifungal drugs in clinical trials. Learn More


Ion Channel Drug Discovery - Therapeutic Opportunities and Technology Progress
In this report, BioSeeker Group has identified and analyzed advancements in novel, ion-channel targeted drug development as well as technology breakthroughs. Learn More

Other selected research from the 'Infectious diseases' category:


Antifungals: 2004 and Beyond
Overview of the most common fungal diseases, already marketed antifungal agents, details from recent studies on approved agents, and information on the recent activities of companies with developmental antifungals. Learn More


Promising Drug Discovery Tools in Antifungal and Status on Emerging Novel Targets
This report will give you a comprehensive overview of the emerging novel drug targets as well as the new generation of antifungal drugs in clinical trials. Learn More